• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

细胞游离 DNA 筛查失败后的细胞遗传学结局:一项基于人群的 35146 例单胎妊娠的回顾性队列研究。

Cytogenetic outcomes following a failed cell-free DNA screen: a population-based retrospective cohort study of 35,146 singleton pregnancies.

机构信息

Prenatal Screening Ontario, Better Outcomes Registry and Network (BORN) Ontario, Ottawa, Canada; Children's Hospital of Eastern Ontario Research Institute, Ottawa, Canada.

Prenatal Screening Ontario, Better Outcomes Registry and Network (BORN) Ontario, Ottawa, Canada.

出版信息

Am J Obstet Gynecol. 2023 Aug;229(2):168.e1-168.e8. doi: 10.1016/j.ajog.2023.01.007. Epub 2023 Jan 7.

DOI:10.1016/j.ajog.2023.01.007
PMID:
36627072
Abstract

BACKGROUND

Cell-free fetal DNA screening is routinely offered to pregnant individuals to screen for aneuploidies. Although cell-free DNA screening is consistently more accurate than multiple-marker screening, it sometimes fails to yield a result. These test failures and their clinical implications are poorly described in the literature. Some studies suggest that a failed cell-free DNA screening result is associated with increased likelihood of cytogenetic abnormalities.

OBJECTIVE

This study aimed to assess the association between a failed cell-free DNA test and common aneuploidies. The objectives were to determine: (1) the proportion of test failures on first and subsequent attempts, and (2) whether a failed cell-free DNA screen on first attempt is associated with increased likelihood of common aneuploidies (trisomies 21, 18, and 13, and sex chromosome aneuploidies).

STUDY DESIGN

This was a population-based retrospective cohort study using data from Ontario's prescribed maternal and child registry, Better Outcomes Registry and Network Ontario. The study included all singleton pregnancies in Ontario with an estimated date of delivery from September 1, 2016 to March 31, 2019 that had a cell-free DNA screening record in the registry. Specific outcomes (trisomies 21, 18, and 13, and sex chromosome aneuploidies) of pregnancies with a failed cell-free DNA screen on first attempt were compared with those of pregnancies with low-risk cell-free DNA-screening results using modified Poisson regression adjusted for funding status (publicly funded vs self-paid), gestational age at screening, method of conception, and maternal age for autosomal aneuploidies.

RESULTS

Our cohort included 35,146 pregnancies that had cell-free DNA screening during the study period. The overall cell-free DNA screening failure rate was 4.8% on first attempt and 2.2% after multiple attempts. An abnormal cytogenetic result for trisomies 21, 18, and 13, or sex chromosome aneuploidies was identified in 19.4% of pregnancies with a failed cell-free DNA screening for which cytogenetic testing was performed. Pregnancies with a failed cell-free DNA screen on first attempt had a relative risk of 130.3 (95% confidence interval, 64.7-262.6) for trisomy 21, trisomy 18, or trisomy 13, and a risk difference of 5.4% (95% confidence interval, 2.6-8.3), compared with pregnancies with a low-risk result. The risk of sex chromosome aneuploidies was not significantly greater in pregnancies with a failed result compared with pregnancies with a low-risk result (relative risk, 2.7; 95% confidence interval, 0.9-7.9; relative difference, 1.2%; 95% confidence interval, -0.9 to 3.2).

CONCLUSION

Cell-free DNA screening test failures are relatively common. Although repeated testing improves the likelihood of an informative result, pregnancies with a failed cell-free DNA screen upon first attempt remain at increased risk for common autosomal aneuploidies, but not sex chromosome aneuploidies.

摘要

背景

游离胎儿 DNA 筛查通常提供给孕妇,以筛查非整倍体。虽然游离 DNA 筛查的准确性始终高于多重标志物筛查,但有时无法得出结果。这些测试失败及其临床意义在文献中描述得很差。一些研究表明,游离 DNA 筛查失败的结果与细胞遗传学异常的可能性增加有关。

目的

本研究旨在评估游离 DNA 检测失败与常见非整倍体之间的关联。目的是确定:(1)首次和后续尝试中检测失败的比例,以及(2)首次尝试时游离 DNA 筛查失败是否与常见非整倍体(三体 21、18 和 13 以及性染色体非整倍体)的可能性增加有关。

研究设计

这是一项基于人群的回顾性队列研究,使用了安大略省规定的母婴登记处、更好的结果登记处和安大略省网络的数据。研究包括所有在安大略省预计分娩日期为 2016 年 9 月 1 日至 2019 年 3 月 31 日的单胎妊娠,并且在登记处有游离 DNA 筛查记录。使用修正泊松回归,根据资金状况(公共资助与自费)、筛查时的孕龄、受孕方式和母体年龄对性染色体非整倍体进行调整,比较首次尝试游离 DNA 筛查失败的妊娠与低风险游离 DNA 筛查结果的特定结局(三体 21、18 和 13 以及性染色体非整倍体)。

结果

我们的队列包括在研究期间进行游离 DNA 筛查的 35146 例妊娠。首次尝试的游离 DNA 筛查失败率为 4.8%,多次尝试后的失败率为 2.2%。对接受游离 DNA 筛查失败且进行细胞遗传学检测的妊娠,发现三体 21、18 和 13 或性染色体非整倍体的异常细胞遗传学结果的比例为 19.4%。首次尝试游离 DNA 筛查失败的妊娠,21 三体、18 三体或 13 三体的相对风险为 130.3(95%置信区间,64.7-262.6),风险差异为 5.4%(95%置信区间,2.6-8.3),与低风险结果的妊娠相比。与低风险结果的妊娠相比,游离 DNA 筛查失败的妊娠中性染色体非整倍体的风险无显著增加(相对风险,2.7;95%置信区间,0.9-7.9;相对差异,1.2%;95%置信区间,-0.9 至 3.2)。

结论

游离 DNA 筛查测试失败较为常见。尽管重复检测可提高获得有效结果的可能性,但首次尝试游离 DNA 筛查失败的妊娠仍有较高的常见常染色体非整倍体风险,但性染色体非整倍体风险没有增加。

相似文献

1
Cytogenetic outcomes following a failed cell-free DNA screen: a population-based retrospective cohort study of 35,146 singleton pregnancies.细胞游离 DNA 筛查失败后的细胞遗传学结局:一项基于人群的 35146 例单胎妊娠的回顾性队列研究。
Am J Obstet Gynecol. 2023 Aug;229(2):168.e1-168.e8. doi: 10.1016/j.ajog.2023.01.007. Epub 2023 Jan 7.
2
Positive predictive value estimates for cell-free noninvasive prenatal screening from data of a large referral genetic diagnostic laboratory.基于大型转诊基因诊断实验室数据的无细胞非侵入性产前筛查的阳性预测值估计
Am J Obstet Gynecol. 2017 Dec;217(6):691.e1-691.e6. doi: 10.1016/j.ajog.2017.10.005. Epub 2017 Oct 13.
3
Cell-free DNA screening for trisomies 21, 18, and 13 in pregnancies at low and high risk for aneuploidy with genetic confirmation.游离胎儿 DNA 筛查在唐氏综合征 21、18 和 13 三体的低危和高危妊娠中的应用,其结果得到了遗传学证实。
Am J Obstet Gynecol. 2022 Aug;227(2):259.e1-259.e14. doi: 10.1016/j.ajog.2022.01.019. Epub 2022 Jan 25.
4
[Retrospective analysis of cell-free fetal DNA prenatal testing of maternal peripheral blood].母体外周血游离胎儿DNA产前检测的回顾性分析
Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2023 Aug 10;40(8):933-938. doi: 10.3760/cma.j.cn511374-20220815-00545.
5
[CLINICAL IMPLEMENTATION OF CELL-FREE DNA ANALYSIS IN MATERNAL BLOOD IN SCREENING FOR ANEUPLOIDIES IN SINGLETON PREGNANCIES].[游离DNA分析在单胎妊娠非整倍体筛查母体血液中的临床应用]
Akush Ginekol (Sofiia). 2016;55(2):10-5.
6
Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women.基于基因组学的非侵入性产前检测用于检测孕妇胎儿染色体非整倍体。
Cochrane Database Syst Rev. 2017 Nov 10;11(11):CD011767. doi: 10.1002/14651858.CD011767.pub2.
7
Noninvasive prenatal screening for fetal trisomies 21, 18, 13 and the common sex chromosome aneuploidies from maternal blood using massively parallel genomic sequencing of DNA.利用DNA大规模平行基因组测序技术对孕妇血液进行无创产前筛查,以检测胎儿21三体、18三体、13三体及常见性染色体非整倍体。
Am J Obstet Gynecol. 2014 Oct;211(4):365.e1-12. doi: 10.1016/j.ajog.2014.03.042. Epub 2014 Mar 19.
8
Prenatal screening for fetal aneuploidy in singleton pregnancies.单胎妊娠胎儿非整倍体的产前筛查。
J Obstet Gynaecol Can. 2011 Jul;33(7):736-750. doi: 10.1016/S1701-2163(16)34961-1.
9
Analysis of cell-free DNA in maternal blood in screening for fetal aneuploidies: updated meta-analysis.母血中游离DNA分析用于胎儿非整倍体筛查:更新的荟萃分析
Ultrasound Obstet Gynecol. 2015 Mar;45(3):249-66. doi: 10.1002/uog.14791. Epub 2015 Feb 1.
10
Performance of cell-free DNA sequencing-based non-invasive prenatal testing: experience on 36,456 singleton and multiple pregnancies.基于游离细胞 DNA 测序的无创性产前检测的性能:36456 例单胎和多胎妊娠的经验。
BMC Med Genomics. 2021 Mar 30;14(1):93. doi: 10.1186/s12920-021-00941-y.

引用本文的文献

1
Factors, pregnancy outcomes, and management associated with non-reportable results in prenatal cell-free DNA testing.与产前游离DNA检测不可报告结果相关的因素、妊娠结局及管理
Arch Gynecol Obstet. 2025 Feb 18. doi: 10.1007/s00404-025-07977-w.